Rulonilimab not checked
Shandong New Time Pharmaceutical Co., LTD · F520
FollowEvery change as it happens, and a Monday email
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “F520: 200 mg per dose, intravenous infusion, infusion time \>30 minutes, Q3W; maximum 2 years. Refer to drug preparation manual for details. Paclitaxel: 175 mg/m², intravenous infusion, infusion time \>3 hours, Q3W, recommended for 6 cycles (may be extended if investigator assesses continued benefit). Refer to package insert for details. Carboplatin: AUC 5, intravenous infusion, infusion time…”In the company’s words, NCT07761429 on ClinicalTrials.gov
- Tested for
- Cancer of Unknown Primary Site, Cervical Cancer
- Main trialPhase 2/3
- “The purpose of this study is to evaluate the efficacy and safety of F520 combined with paclitaxel plus carboplatin as first-line treatment for cancer of unknown primary.This study consists of two parts, with a total planned enrollment of 402 patients.Primary Endpoint is Objective Response Rate (ORR) assessed by Independent Review Committee (IRC) based on RECIST 1.1 Secondary Endpoints included ORR、PFS、DOR;Incidence and severity of Adverse Events (AE), Serious Adverse Events (SAE), and abnormal laboratory parameters.”In the company’s words, NCT07761429 on ClinicalTrials.gov
- Other names
- F520
Other drugs for Cervical Cancer
- SocazolimabLee's Pharmaceutical Limited · Phase 3
- 9-valent Human Papillomavirus Recombinant VaccineShanghai Bovax Biotechnology Co., Ltd. · Phase 3
- JSKN033Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Phase 3
- Bulumtatug fuvedotinMabwell · Phase 3
- SHR-A2102Hengrui · Phase 3
- SYS6002CSPC · Phase 3
Coming up2
- 30 Dec 2027Phase 2/3 trial completes · ClinicalTrials.gov
- Sep 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Recruiting | 30 Dec 2027 | A Phase II/III Study of F520 Combined With Paclitaxel Plus Carboplatin in the Treatment of Cancer of Unknown Primary (CUP) | |
| Phase 2/3Enrolling by invitation | Sep 2028 | A Phase Ⅱ/Ⅲ Study of Rulonilimab Plus Chemotherapy± Bevacizumab for the First-Line Treatment of Persistent, Recurrent or Metastatic Cervical Cancer | |
| Phase 2/3Unknown | 1 Aug 2025 | the Efficacy and Safety of Rulonilimab in Combination With Lenvatinib in Hepatocellular Carcinoma | |
| Phase 2Unknown | 31 Dec 2023 | A Phase II Study to Evaluate the Efficacy and Safety of F520 Combined With F007 in Patients With RR DLBCL | |
| Phase 2Unknown | 25 Oct 2024 | A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | |
| Phase 1/2Unknown | 22 May 2024 | Efficacy and Safety Study of F520 Combined With Lenvatinib in the Treatment of Patients With Advanced Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026